Reactive dose escalation of infliximab in patients with Crohn's disease in TAILORIX leads to improved outcomes

被引：0
|
作者：
Dreesen, E. [1 ]
Laharie, D. [2 ]
Lambrecht, G. [3 ]
Bossuyt, P. [4 ]
Buisson, A. [5 ]
Filippi, J. [6 ]
Van Hootegem, P. [7 ]
D'Haens, G. [8 ]
Vermeire, S. [9 ,10 ]
Gils, A. [1 ]
机构：
[1] Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium
[2] Hosp Haut Leveque, Bordeaux, France
[3] Damiaan Hosp, Oostende, Belgium
[4] Imelda Hosp, Bonheiden, Belgium
[5] Hosp Estaing, Clermont Ferrand, France
[6] Hosp Archet, Nice, France
[7] Sint Lucas Hosp, Brugge, Belgium
[8] Acad Med Ctr, Amsterdam, Netherlands
[9] Univ Hosp Leuven, Dept Gastroenterol & Hepatol, Leuven, Belgium
[10] Katholieke Univ Leuven, Dept Chron Dis Metab & Ageing, Leuven, Belgium
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P572
引用
收藏
页码：S396 / S397
页数：3
相关论文
共 50 条
  • [21] The impact of proactive versus reactive drug monitoring of infliximab on treatment outcomes in patients with crohn's disease
    Zhang, Yue
    Jiang, Wenyu
    Xu, Chenjing
    Tian, Jiahui
    Chen, Jie
    Zhang, Hongjie
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2024, 59 (03) : 269 - 279
  • [22] Factors Associated With Ustekinumab Dose Escalation in Patients With Crohn's Disease
    Njie, Cheikh
    Dalal, Rahul S.
    Allegretti, Jessica R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S368 - S368
  • [23] Efficacy, Safety, and Pharmacokinetics of Infliximab Dose Escalation in Pediatric Patients With Crohn's Disease or Ulcerative Colitis: An Analysis of the DEVELOP Registry
    Dubinsky, Marla C.
    Markowitz, James
    Busse, Christopher
    Koletzko, Sibylle
    Winter, Harland
    Baldassano, Robert
    Colletti, Richard
    Kugathasan, Subra
    Ruemmele, Frank
    Griffiths, Anne
    Gasink, Christopher
    Adedokun, Omoniyi
    Izanec, James L.
    Gao, Long-Long
    Ma, Tony
    Ott, Elyssa
    Hyams, Jeffrey
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S592 - S593
  • [24] Previous Non-Response to Infliximab Predicts Early Dose-Escalation in Adalimumab Treated Crohn's Disease Patients
    Bultman, Evelien
    West, Rachel L.
    van Liere-Baron, Astrid
    Kuipers, Ernst J.
    Zelinkova, Zuzana
    Woude, Janneke V.
    GASTROENTEROLOGY, 2010, 138 (05) : S701 - S702
  • [25] Drug-concentration versus symptom-driven dose adaptation of Infliximab in patients with active Crohn's disease: a prospective, randomised, multicentre trial (Tailorix)
    D'Haens, G.
    Vermeire, S.
    Lambrecht, G.
    Baert, F.
    Bossuyt, P.
    Nachury, M.
    Buisson, A.
    Bouhnik, Y.
    Filippi, J.
    Vande Woude, J.
    Van Hootegem, P.
    Moreau, J.
    Louis, E.
    Franchimont, D.
    De Vos, M.
    Mana, F.
    Peyrin-Biroulet, L.
    Brixi, H.
    Allez, M.
    Caenepeel, P.
    Aubourg, A.
    Oldenburg, B.
    Pierik, M.
    Gils, A.
    Chevret, S.
    Laharie, D.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S24 - S24
  • [26] THE EFFECT OF INFLIXIMAB DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH ANTIBODIES TO INFLIXIMAB
    Tun, Gloria S. Z.
    Marshall, Laura
    Thompson, Laura
    Campbell, Rebecca
    Hale, Melissa F.
    Chew, Thean S.
    Brooks, Alenka J.
    Robinson, Kerry
    Lobo, Alan J.
    GUT, 2019, 68 : A61 - A62
  • [27] The effect of infliximab dose escalation in inflammatory bowel disease patients with antibodies to infliximab
    Tun, Gloria S. Z.
    Robinson, Kerry
    Marshall, Laura
    Wright, Alison
    Thompson, Laura
    Wild, Graeme
    Sargur, Ravishankar
    Brooks, Alenka J.
    Hale, Melissa F.
    Chew, Thean S.
    Lobo, Alan J.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (03) : 295 - 301
  • [28] EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN CROHN'S DISEASE
    Ollech, Jacob
    Normatov, Inessa
    Peleg, Noam
    Patel, Shivani
    Rai, Victoria
    Wang, Jingzhou D.
    Yi, Yangtian
    Singer, Jorie
    Dalal, Sushila
    Sakuraba, Atsushi
    Cohen, Russell D.
    Rubin, David T.
    Pekow, Joel R.
    GASTROENTEROLOGY, 2020, 158 (06) : S961 - S961
  • [29] OUTCOMES OF ACCELERATED VS. STANDARD INFLIXIMAB INDUCTION DOSE IN CROHN'S DISEASE
    Almomen, Hisham S.
    Sayed, Amr
    Chipkin, Benjamin
    Nawaz, Ahmad
    Gaidos, Jill K.
    Proctor, Deborah D.
    Al Bawardy, Badr
    GASTROENTEROLOGY, 2023, 164 (06) : S1132 - S1132
  • [30] Durability of Infliximab Dose Intensification in Crohn’s Disease
    Kirk K. Lin
    Fernando Velayos
    Elena Fisher
    Jonathan P. Terdiman
    Digestive Diseases and Sciences, 2012, 57 : 1013 - 1019
12345